{"title_page": "Oxford BioMedica", "text_new": "{{EngvarB|date=September 2013}}\n{{Use dmy dates|date=September 2013}}\n{{Refimprove|date=April 2009}}\n{{Infobox company\n| logo = Oxford BioMedica logo.svg\n| name   = ''Oxford BioMedica plc''\n| type   = Public company ({{LSE|OXB}})\n| foundation     = 1995\n| num_employees  = 450<ref>{{cite web | last = | first = | authorlink = | coauthors = | url = http://consilium-comms.com/news-detail.aspx?news=3862| work = | publisher = Consilium Strategic Communications Limited| date = 5 December 2016| title = Oxford BioMedica Notes Findings Reported by Novartis on CTL-019 at 58th American Society of Hematology Annual Meeting| format = | doi = | accessdate = 25 December 2016 }}</ref>\n| revenue        = {{currency|amount=15.9 million|code=GBP}} (May 2016)<ref name=\"2015 report\">{{cite web | last = | first = | authorlink = | coauthors = | title = Annual Report and Accounts 2015| work = | publisher = Oxford BioMedica | date = | url = http://www.oxfordbiomedica.co.uk/uploads/financial-report/oxb-ar15.pdf| format = | doi = | accessdate = 25 December 2016 }}</ref>\n| net_income   = {{currency|amount=-14.1 million|code=GBP}} (May 2016)<ref name=\"2015 report\"/>\n| industry       = [[Pharmaceutical industry|Pharma]]\n| website = [http://www.oxb.com www.oxb.com]\n}}\n\n'''Oxford Biomedica''' (LSE: OXB) is a gene and cell therapy company specialising in the development of [[Gene therapy|gene-based medicines]]. It was established in 1995 as a spin out from [[Oxford University]].<ref>[http://www.hoovers.com/oxford-biomedica/--ID__103385--/free-co-factsheet.xhtml Hoover's | A D&B Company]. Hoovers.com.</ref> The Company\u2019s development pipeline includes investigational treatments for cancer, [[Parkinson's disease]] and [[retinopathy]]. The executive management team includes John Dawson, Chief Executive Officer and Dmitry Zamoryakhin, the company\u2019s Chief Medical Officer.<ref>{{Cite web|url=https://www.oxfordbiomedica.co.uk/about/board|title=Board of Directors {{!}} OxfordBiomedica|website=www.oxfordbiomedica.co.uk|access-date=2020-04-02}}</ref> \n\nIn 2018, Oxford Biomedica's gene therapy for Parkinson's disease became the subject of a commercialization deal with [[Axovant Sciences]].<ref>{{cite web|title=Oxford BioMedica seals $842m Parkinson\u2019s therapy deal with Axovant\n|url=https://www.ft.com/content/027f49c6-6970-11e8-b6eb-4acfcfb08c11|first1=Clive|last1=Cookson|date=6 June 2018|access-date=27 June 2018}}</ref>\n\nIn May 2019, the company announced an investment by [[Novo Holdings A/S|Novo Holdings]] for a stake of 10.1% in Oxford Biomedica, totaling $55 million (USD) to develop its gene therapy technology.<ref>{{Cite web|url=https://www.labiotech.eu/medical/oxford-biomedica-novo-gene-therapy/|title=\u20ac60M Investment to Boost Oxford Biomedica\u2019s Gene and Cell Therapies|last=Medical|first=Jonathan Smith-29/05/2019 1 min-|date=2019-05-29|website=Labiotech.eu|language=en-US|access-date=2020-03-13}}</ref> The firm also has collaborations with Sanofi, Novartis and other groups to provide lentiviral vector manufacturing.<ref>{{Cite web|url=https://www.evaluate.com/vantage/articles/analysis/plenty-choice-remains-buyers-gene-therapy|title=Plenty of choice remains for buyers of gene therapy|date=2019-12-20|website=Evaluate.com|language=en|access-date=2020-03-26}}</ref>\n\nIn November 2019, [[Microsoft]] announced a partnership with Oxford Biomedica to improve the next generation of [[Cell (biology)|cell]] and [[gene delivery]] technology using the cloud and [[Machine learning|machine learning,]] contributing large data sets for analysis via the [[Microsoft Azure]] intelligent cloud platform to develop in-silico models and novel algorithms to help provide long-term and curative treatments for a wide range of diseases.<ref>{{Cite web|url=http://www.pharmatimes.com/magazine/2019/november_2019/transforming_the_landscape|title=Transforming the landscape|last=Rut|first=Andrew|date=2019-10-28|website=PharmaTimes|language=en|access-date=2020-03-04}}</ref>\n\nOn December 19, 2019, the company announced that it has extended its commercial supply agreement with Novartis for the manufacture of lentiviral vectors for the [[Novartis]] [[Chimeric antigen receptor T cell|CAR-T]] portfolio including five lentiviral vectors for CAR-T products, which builds on the existing three-year commercial supply agreement signed by the parties in July 2017.<ref>{{Cite web|url=https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-extends-commercial-supply-agreement-five-years-manufacture|title=Oxford Biomedica Extends Commercial Supply Agreement by Five Years for Manufacture of Lentiviral Vectors {{!}} OxfordBiomedica|website=www.oxfordbiomedica.co.uk|access-date=2020-02-25}}</ref>\u00a0 \u00a0 \n\n== Finance ==\nThe company had raised a total of \u00a3137 million to fund its research and clinical programmes.\nThe IPO on the Alternative Investment Market of the London Stock Exchange in December 1996 raised \u00a35.1 million.\n\nA further \u00a36 million was raised by a rights issue and placing in March/April 1998, \u00a33.6 million by a rights issue in March 1999, \u00a35.2 million in a Placing in January 2000 and \u00a38.8 million in a Placing in August 2000.\n\nOxford BioMedica's move to the official list of the London Stock Exchange was completed in April 2001 along with a \u00a335.5 million fund raising, before costs, from a placing and open offer.\n\nA Rights Issue for \u00a322.1 million, before costs, was completed in October 2003. A further share offering in December 2005 raised \u00a330.1 million before expenses, including an investment of \u00a32.9 million by Sigma-Aldrich\n<ref>[http://www.oxfordbiomedica.co.uk/financing.asp ] {{webarchive |url=https://web.archive.org/web/20090422104906/http://www.oxfordbiomedica.co.uk/financing.asp |date=22 April 2009 }}</ref>{{Better source|date=April 2009}}. A placing and open offer in December 2010 raised \u00a320 million.\n\n== References ==\n{{reflist|colwidth=30em}}\n\n{{Pharmaceutical industry in the United Kingdom}}\n\n[[Category:Biopharmaceutical companies]]\n[[Category:Pharmaceutical companies of the United Kingdom]]\n[[Category:Pharmaceutical companies established in 1995]]\n", "text_old": "{{EngvarB|date=September 2013}}\n{{Use dmy dates|date=September 2013}}\n{{Refimprove|date=April 2009}}\n{{Infobox company\n| logo = Oxford BioMedica logo.svg\n| name   = ''Oxford BioMedica plc''\n| type   = Public company ({{LSE|OXB}})\n| foundation     = 1995\n| num_employees  = 450<ref>{{cite web | last = | first = | authorlink = | coauthors = | url = http://consilium-comms.com/news-detail.aspx?news=3862| work = | publisher = Consilium Strategic Communications Limited| date = 5 December 2016| title = Oxford BioMedica Notes Findings Reported by Novartis on CTL-019 at 58th American Society of Hematology Annual Meeting| format = | doi = | accessdate = 25 December 2016 }}</ref>\n| revenue        = {{currency|amount=15.9 million|code=GBP}} (May 2016)<ref name=\"2015 report\">{{cite web | last = | first = | authorlink = | coauthors = | title = Annual Report and Accounts 2015| work = | publisher = Oxford BioMedica | date = | url = http://www.oxfordbiomedica.co.uk/uploads/financial-report/oxb-ar15.pdf| format = | doi = | accessdate = 25 December 2016 }}</ref>\n| net_income   = {{currency|amount=-14.1 million|code=GBP}} (May 2016)<ref name=\"2015 report\"/>\n| industry       = [[Pharmaceutical industry|Pharma]]\n| website = [http://www.oxb.com www.oxb.com]\n}}\n\n'''Oxford Biomedica''' (LSE: OXB) is a gene and cell therapy company specialising in the development of [[Gene therapy|gene-based medicines]]. It was established in 1995 as a spin out from [[Oxford University]].<ref>[http://www.hoovers.com/oxford-biomedica/--ID__103385--/free-co-factsheet.xhtml Hoover's | A D&B Company]. Hoovers.com.</ref> The Company\u2019s development pipeline includes investigational treatments for cancer, [[Parkinson's disease]] and [[retinopathy]]. \n\nIn 2018, Oxford Biomedica's gene therapy for Parkinson's disease became the subject of a commercialization deal with [[Axovant Sciences]].<ref>{{cite web|title=Oxford BioMedica seals $842m Parkinson\u2019s therapy deal with Axovant\n|url=https://www.ft.com/content/027f49c6-6970-11e8-b6eb-4acfcfb08c11|first1=Clive|last1=Cookson|date=6 June 2018|access-date=27 June 2018}}</ref>\n\nIn May 2019, the company announced an investment by [[Novo Holdings A/S|Novo Holdings]] for a stake of 10.1% in Oxford Biomedica, totaling $55 million (USD) to develop its gene therapy technology.<ref>{{Cite web|url=https://www.labiotech.eu/medical/oxford-biomedica-novo-gene-therapy/|title=\u20ac60M Investment to Boost Oxford Biomedica\u2019s Gene and Cell Therapies|last=Medical|first=Jonathan Smith-29/05/2019 1 min-|date=2019-05-29|website=Labiotech.eu|language=en-US|access-date=2020-03-13}}</ref> The firm also has collaborations with Sanofi, Novartis and other groups to provide lentiviral vector manufacturing.<ref>{{Cite web|url=https://www.evaluate.com/vantage/articles/analysis/plenty-choice-remains-buyers-gene-therapy|title=Plenty of choice remains for buyers of gene therapy|date=2019-12-20|website=Evaluate.com|language=en|access-date=2020-03-26}}</ref>\n\nIn November 2019, [[Microsoft]] announced a partnership with Oxford Biomedica to improve the next generation of [[Cell (biology)|cell]] and [[gene delivery]] technology using the cloud and [[Machine learning|machine learning,]] contributing large data sets for analysis via the [[Microsoft Azure]] intelligent cloud platform to develop in-silico models and novel algorithms to help provide long-term and curative treatments for a wide range of diseases.<ref>{{Cite web|url=http://www.pharmatimes.com/magazine/2019/november_2019/transforming_the_landscape|title=Transforming the landscape|last=Rut|first=Andrew|date=2019-10-28|website=PharmaTimes|language=en|access-date=2020-03-04}}</ref>\n\nOn December 19, 2019, the company announced that it has extended its commercial supply agreement with Novartis for the manufacture of lentiviral vectors for the [[Novartis]] [[Chimeric antigen receptor T cell|CAR-T]] portfolio including five lentiviral vectors for CAR-T products, which builds on the existing three-year commercial supply agreement signed by the parties in July 2017.<ref>{{Cite web|url=https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-extends-commercial-supply-agreement-five-years-manufacture|title=Oxford Biomedica Extends Commercial Supply Agreement by Five Years for Manufacture of Lentiviral Vectors {{!}} OxfordBiomedica|website=www.oxfordbiomedica.co.uk|access-date=2020-02-25}}</ref>\u00a0 \u00a0 \n\n== Finance ==\nThe company had raised a total of \u00a3137 million to fund its research and clinical programmes.\nThe IPO on the Alternative Investment Market of the London Stock Exchange in December 1996 raised \u00a35.1 million.\n\nA further \u00a36 million was raised by a rights issue and placing in March/April 1998, \u00a33.6 million by a rights issue in March 1999, \u00a35.2 million in a Placing in January 2000 and \u00a38.8 million in a Placing in August 2000.\n\nOxford BioMedica's move to the official list of the London Stock Exchange was completed in April 2001 along with a \u00a335.5 million fund raising, before costs, from a placing and open offer.\n\nA Rights Issue for \u00a322.1 million, before costs, was completed in October 2003. A further share offering in December 2005 raised \u00a330.1 million before expenses, including an investment of \u00a32.9 million by Sigma-Aldrich\n<ref>[http://www.oxfordbiomedica.co.uk/financing.asp ] {{webarchive |url=https://web.archive.org/web/20090422104906/http://www.oxfordbiomedica.co.uk/financing.asp |date=22 April 2009 }}</ref>{{Better source|date=April 2009}}. A placing and open offer in December 2010 raised \u00a320 million.\n\n== References ==\n{{reflist|colwidth=30em}}\n\n{{Pharmaceutical industry in the United Kingdom}}\n\n[[Category:Biopharmaceutical companies]]\n[[Category:Pharmaceutical companies of the United Kingdom]]\n[[Category:Pharmaceutical companies established in 1995]]\n", "name_user": "Kristindemauro", "label": "safe", "comment": "added a sentence about Oxford biomedica's management team changes", "url_page": "//en.wikipedia.org/wiki/Oxford_BioMedica"}
